SCHEMBL6338247

SCHEMBL6338247

COc1cc2ccc(COC(C)=O)cc2cc1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.49
ALDH1A1 P00352 3/20 0.47
CA2 P00918 1/20 0.47
KDM4E B2RXH2 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
NPC1 O15118 1/20 0.45
LMNA P02545 1/20 0.45
TP53 P04637 1/20 0.45
CYP1A2 P05177 1/20 0.45
MAPT P10636 1/20 0.45
MAOA P21397 1/20 0.45
SLC6A2 P23975 1/20 0.45
RAB9A P51151 1/20 0.45
SLC6A3 Q01959 1/20 0.45
PTGS1 P23219 2/20 0.44
AKR1C3 P42330 1/20 0.44
AKR1C2 P52895 1/20 0.44
HPGD P15428 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11320167 0.88 CYP3A4 (0.56) CYP3A4ALDH1A1CA2KDM4ESMN1; SMN2
SCHEMBL4186791 0.88 CYP3A4 (0.59) CYP3A4ALDH1A1CA2KDM4ESMN1; SMN2
SCHEMBL6481775 0.85 ALDH1A1 (0.56) CYP3A4ALDH1A1CA2KDM4ESMN1; SMN2
SCHEMBL12431386 0.82 GAA (0.61) CYP3A4ALDH1A1LMNACYP1A2MEN1
SCHEMBL14070555 0.81 CYP3A4 (0.53) CYP3A4ALDH1A1CA2KDM4ESMN1; SMN2
SCHEMBL487508 0.81 ALDH1A1 (0.61) CYP3A4ALDH1A1CA2CYP1A2RAB9A
SCHEMBL10996267 0.81 CYP3A4 (0.53) CYP3A4ALDH1A1CA2KDM4ESMN1; SMN2
SCHEMBL13034139 0.79 CYP3A4 (0.50) CYP3A4ALDH1A1CA2SMN1; SMN2MAPT
SCHEMBL30122259 0.79 TSHR (0.61) CYP3A4ALDH1A1LMNAPTGS1GAA
SCHEMBL357115 0.79 TSHR (0.61) CYP3A4ALDH1A1LMNAPTGS1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6903114-B2 Derivatives of naphthalene with COMT inhibiting activity ORION CORPORATION (FI) 2005-06-07 US disclosed
US-20040034011-A1 Derivatives of naphthalene with comt inhibiting activity ORION CORPORATION (FI) 2004-02-19 US disclosed
EP-1317411-A1 DERIVATIVES OF NAPHTHALENE WITH COMT INHIBITING ACTIVITY ORION CORPORATION (FI) 2003-06-11 EP disclosed
WO-2002022551-A1 DERIVATIVES OF NAPHTHALENE WITH COMT INHIBITING ACTIVITY ORION CORPORATION (FI) 2002-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034011-A1 Derivatives of naphthalene with comt inhibiting activity COMT, CYP1A1, CYP1B1 CYP3A4 33/4885ALDH1A1 39/4885CA2 4573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.